This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014;124:363–73. https://doi.org/10.1182/blood-2014-01-514786.
Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin 2019;37:569–82. https://doi.org/10.1016/j.det.2019.05.014.
Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017;129:22–9. https://doi.org/10.1182/blood-2016-08-686659.
Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med. 2010;134:1220–4. https://doi.org/10.5858/2008-0679-RS.1.
Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets. 2021;25:761–71. https://doi.org/10.1080/14728222.2021.1992383.
Martini DJ, Chen YB, DeFilipp Z. Recent FDA approvals in the treatment of graft-versus-host disease. Oncologist 2022;27:685–93. https://doi.org/10.1093/oncolo/oyac076.
Braun LM, Zeiser R. Kinase inhibition as treatment for acute and chronic graft-versus-host disease. Front Immunol. 2021;12:760199. https://doi.org/10.3389/fimmu.2021.760199.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85:863–72. https://doi.org/10.1016/j.jaad.2021.04.085.
Bloudek L, Eichenfield LF, Silverberg JI, Joish VN, Lofland JH, Sun K, et al. Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies. Am J Clin Dermatol 2023;24:109–17. https://doi.org/10.1007/s40257-022-00734-8.
Markova A, Pan A, Dusza S, Chowdhury A, Kukoyi O, Perales MA, et al. Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 Phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Blood. 2021;138:3915.
Website: Opzelura™: Incyte Corporation. https://www.opzelura.com/prescribing-information.pdf. Date Revised: 7/2022. Date Accessed: 09/01/2023
Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–37. https://doi.org/10.1182/blood-2016-07-686642.
Acknowledgements
We would like to thank clinical staff, patients, and families at Cincinnati Children’s Hospital Medical Center.
Author information
Authors and Affiliations
Contributions
ZH and PK designed the study, collected data, and wrote the manuscript. ATC contributed to analyzing, interpreting results, reviewing the manuscript critically for edits. AF and SMD contributed patients and reviewed the manuscript critically for edits.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hudda, Z., Flannery, A., Teusink-Cross, A. et al. Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD. Bone Marrow Transplant 59, 425–427 (2024). https://doi.org/10.1038/s41409-023-02181-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-02181-3
This article is cited by
-
Ruxolitinib
Reactions Weekly (2024)